• Hisashi Nagahara, Eiji Noda, Kiyoshi Maeda, Toru Inoue, Toshiki Hirakawa, Tsuyoshi Hasegawa, Masatsune Shibutani, and Kosei Hirakawa.
• Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
• Gan To Kagaku Ryoho. 2013 Sep 1;40(9):1181-3.

AbstractThirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin. All patients received oxaliplatin as adjuvant or first-line chemotherapy. The mFOLFOX6 and CapeOX groups included 3 and 10 cases, respectively, and the average treatment regimens were 8 and 5 doses, respectively. Before receiving pregabalin, sensory neuropathy was classified as Grade 3 in 2 patients, as Grade 2 in 8 patients, and as Grade 1 in 3 patient. The average amount of pregabalin administered to patients was 237 (range: 150-450) mg. After administering pregabalin, we observed improvements in 8 neuropathy cases (61. 5%)within approximately 2 weeks. All side effects were mild. In this study, pregabalin was shown to positively impact sensory neuropathy resulting from oxaliplatin treatment and to enable the long-term use of oxaliplatin-based chemotherapy.

21 keywords...

hide…